Skip to main content

SpyGlass Pharma, Inc.

SGP
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001778922

In the last 90 days, SpyGlass Pharma, Inc. insiders filed 1 open-market purchase and 0 sales; 69 institutions reported holding it in 13F filings for Q3 2026, worth $687.8M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 13, 2026, 1:21 AM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of SpyGlass Pharma, Inc., annual
Line itemFY2025
Period endDec 31, 2025
Filing10-K
ReportedMar 26, 2026
Operating expenses$41.4M
Research and development$29.2M
Selling, general and administrative$12.3M
Operating income-$41.4M
Income tax$0
Net income-$39.9M
EPS, basic$-17.98
EPS, diluted$-17.98
Weighted shares, basic2.22M
Weighted shares, diluted2.22M

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of SpyGlass Pharma, Inc., annual
Line itemFY2025!
Period endDec 31, 2025
Filing10-K
ReportedMar 26, 2026
Cash and equivalents$96.4M
Total current assets$108.8M
Property, plant and equipment$2.34M
Total assets$115.9M
Accounts payable$2.70M
Total current liabilities$8.58M
Total liabilities$10.2M
Shareholders' equity-$98.8M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of SpyGlass Pharma, Inc., annual
Line itemFY2025
Period endDec 31, 2025
Filing10-K
ReportedMar 26, 2026
Operating cash flow-$32.7M
Capital expenditures$789.0K
Free cash flow-$33.5M
Stock-based compensation$2.79M
Share buybacks$1.45M
Investing cash flow-$11.8M
Financing cash flow$124.6M
Net change in cash$80.1M

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for SpyGlass Pharma, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 2, 202633.5M–SEC
Jul 29, 202633.4M–SEC
Apr 20, 202633.4M–SEC
Mar 1, 202633.4M–SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.